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ABSTRACT 
Background: Venlafaxine is a structurally novel antidepressant that is be- 
lieved to potentiate monoamine activity in the central nervous system. In pre- 
clinical studies, venlafaxine was shown to inhibit the neuronal uptake of sero- 
tonin and norepinephrine and, to a lesser degree, dopamine reuptake, but was 
without effect on monoamine oxidase (MAO) activity. Clinical trial results from 
-3000 patients suggest that venlafaxine is a safe and effective antidepressant 
with the potential to invoke an early onset of clinical activity. 
Objective: The purpose of this &week, open-label, uncontrolled, multi- 
center, Phase IV study was to examine the extent of remission and symptom 
relief in outpatients and inpatients with major depressive disorder treated with 
venlafaxine. 
Methods: This study was conducted at 12 centers across Belgium and Lux- 
embourg. Consecutive, severely depressed inpatients and moderately de- 
pressed outpatients aged 18 to 70 years were eligible. Patients were adminis- 
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tered open-label venlafaxine for 8 weeks. Dosing was initiated at venlafaxine 
75 mg/d (37.5 mg BID), with dose adjustments made throughout the study, to 
a maximum daily dose of 375 mg for inpatients and 225 mg for outpatients. 
Results were measured using the Hamilton Depression (HAM-D) scale, the 
Montgomery-Asberg Depression Rating Scale (MADRS), and the Clinical Global 
Impression (CGI) scale. 
Results: A total of 149 consecutive patients (84 females, 65 males; mean age, 
46.5 years; 88 outpatients, 61 inpatients) were enrolled; the intent-to-treat (ITT) 
population comprised 144 patients (84 outpatients, 60 inpatients); 111 patients 
(64 outpatients, 47 inpatients) completed the study. At the week 8 visit, 71.3% 
of patients (77/108) were considered to be responders according to the HAM-D 
scale; 73.8% (79/107) according to the MADRS; and 78.7% (85/108) according to 
the CGI scale. A sustained response was achieved in 33.3% of the ITT population 
(48/144), and at week 8, 50.8% of outpatients (32/63) and 37.8% of inpatients 
(17/45) were in remission according to the HAM-D scale. Venlafaxine was well 
tolerated at all doses, with the most frequently experienced adverse events 
(AEs) being nausea, sweating, and headache. Fewer inpatients than outpatients 
reported ~1 AE (57.4% [35/61] and 73.9% [65/88], respectively), despite receiv- 
ing a higher maximum daily dose of venlafaxine. 
Conclusion: The results of this study indicate that venlafaxine was a toler- 
able and effective antidepressant in both outpatients and inpatients, with a 
significant proportion of patients achieving remission. 
Key words: venlafaxine, depression, remission, antidepressant. (CUW Ther 
Res Clin Exp. 2002;63:475-485) 
INTRODUCTION 
Venlafaxine is a structurally novel antidepressant that is believed to potentiate 
monoamine activity in the central nervous system. In a preclinical study,’ ven- 
lafaxine was shown to inhibit the neuronal uptake of serotonin and norepineph- 
rine and, to a lesser degree, dopamine reuptake, but was without effect on 
monoamine oxidase (MAO) activity. The drug displays no affinity for rat brain 
muscarinic, cholinergic, histaminergic, or adrenergic receptors and, unlike 
other antidepressants, produces a rapid onset of noradrenergic subsensitivity.’ 
The human pharmacokinetic profile of venlafaxine was assessed in >200 
patients in earlier Phase I and II studies. 3*4 Orally administered venlafaxine is 
rapidly absorbed, with peak plasma venlafaxine concentrations attained within 
2 hours3 and plasma venlafaxine concentrations proportional to dose over the 
range of 25 to 75 mg every 8 hours. Venlafaxine is extensively metabolized in 
the liver and eliminated predominantly by the kidney.4 The major urinary me- 
tabolite O-desmethylvenlafaxine also demonstrates serotonin and norepineph- 
rine uptake inhibition in preclinical models, thus enhancing the pharmacologic 
efficacy of venlafaxine.’ 
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Clinical trial results from -3000 patients suggest that venlafaxine is a safe and 
effective antidepressant with the potential to invoke an early onset of clinical 
activity. In randomized, double-blind studies of venlafaxine with imipramine,5-7 
trazodone,8 and placebog-” in depressed patients, venlafaxine was more effec- 
tive than placebo in relieving the symptoms of depression, and performed as 
well as, and in some cases better than, the comparative antidepressant drugs. 
In additional placebo-controlled clinical trials12-14 performed in a generally 
equivalent manner, the most frequently reported adverse events (AEs) associ- 
ated with venlafaxine administration were nausea, somnolence, dry mouth, and 
dizziness. These events were first observed after initial venlafaxine treatment 
and often subsided with continued drug administration. Dose-related increases 
in blood pressure (2 mm Hg mean increase in supine diastolic blood pressure) 
and slight increases in heart rate also were reported. 
This 8week, open-label, uncontrolled, multicenter, Phase IV study, designed to 
represent typical clinical use of venlafaxine, assessed its ability to produce 
remission and symptom relief (defined as a score on the Hamilton Depression 
[HAM-D] scale ~8) in outpatients and inpatients with major depressive disorder. 
PATIENTS AND METHODS 
This study was conducted at 12 centers across Belgium and Luxembourg. All 
study procedures were conducted in accordance with the ethical principles 
detailed in the Declaration of Helsinki. Two hundred consecutive male and 
female outpatients and inpatients aged 18 to 70 years who had provided written 
informed consent were to be enrolled in this study. lnpatients were to have a 
minimum baseline score of 25 on the HAM-D scale and to be considered by the 
investigator to be severely depressed. Outpatients were to have a HAM-D score 
between 18 and 25 at baseline and to be considered moderately depressed. 
Women of childbearing potential were to have a negative pregnancy test result 
at baseline and were to use contraceptives throughout the study. Pregnant or 
breast-feeding women were not enrolled. 
Also excluded were patients with concomitant psychiatric disease or per- 
sonality disorder or known clinically significant abnormal laboratory test re- 
sults. Patients were excluded if they had received any antidepressant, antipsy- 
chotic, or investigational drug within 7 days of baseline (unless the drug was 
permitted during the study period); MAO inhibitors within 14 days of baseline; 
fluoxetine within 21 days of baseline; or electroconvulsive therapy within 30 
days of baseline. Medications prohibited during the study included psycho- 
tropic drugs, nonpsychotropic drugs with psychotropic effects (unless the 
dose had been stable for ~-1 month), fluoxetine, MAO inhibitors, and antide- 
pressants (except venlafaxine). Patients were, however, permitted to take ~4 
mg/d lorazepam or ~2 mg/d lormetazepam, as well as other medications, to 
treat intercurrent medical conditions. Outpatients who were acutely suicidal 
were not enrolled. 
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Patients were administered open-label venlafaxine for 8 weeks. Venlafaxine 
was taken orally, with meals. Outpatients initially received 75 mg (37.5 mg BID) 
venlafaxine for 2 weeks. Dose increases were allowed, in 75-mg increments at 
minimum intervals of 2 weeks, to a maximum daily dose of 225 mg (75 mg TID) 
to optimize the response. Inpatients received 75 mg/d (37.5 mg BID) venlafaxine 
for 3 days, followed by 150 mg/d (75 mg BID) for 6 days. Again, dose increases 
were allowed, in 75-mg increments at minimum intervals of 3 days, to a maxi- 
mum daily dose of 375 mg (150 mg in the morning and evening and 75 mg at 
noon). The decision to increase the dose of venlafaxine, or to reduce the dose 
in patients showing a sustained response, was based on tolerance and the 
clinical judgment of the investigator. However, outpatients unable to tolerate 275 
mg/d and inpatients unable to tolerate ~150 mg/d were withdrawn from the study. 
At baseline (day l), patients were assessed for eligibility, and a complete 
medical and psychiatric history was taken using patients’ medical records and 
interviews. From baseline to week 8, disease status was assessed using the 
HAM-D scale, the Montgomery-Asberg Depression Rating Scale (MADRS), and 
the Clinical Global Impression (CGI) scale. AEs and the use of concomitant 
medications also were recorded at these visits. Patients were withdrawn from 
the study if they experienced a marked increase in depression-especially the 
emergence of suicidal thoughts requiring precautionary action-that could not 
be controlled using study procedures. 
Statistical Analyses 
Statistical analyses were performed by Pharmaceutical Research Associates 
International (Charlottesville, Va) using the SAS software package version 6.08 
(SAS Institute Inc, Cary, NC) and was based on pooled data from individual 
study centers. The intent-to-treat (ITT) data set comprised all patients who had 
received 21 dose of venlafaxine and who had 21 assessment during the treat- 
ment period, either while receiving therapy or within 3 days of the last dose. All 
analyses of efficacy and of vital signs for safety were performed using this 
population. 
The primary efficacy variables were the week 8 on-therapy HAM-D and 
MADRS total scores. These scores were analyzed on the basis of all patients 
remaining in the study at each visit and on the basis of the last observation 
carried forward (LOCF). Vital-sign data were analyzed using summary statistics 
of changes from baseline and the incidence of vital signs outside predefined 
levels of concern. 
Patients were considered to be responders if their total HAM-D score had 
decreased 250% from baseline, with an equivalent definition for MADRS- 
defined responders. They were considered overall responders if they were 
either a HAM-D- or MADRS-defined responder and they had a CGI score of 1 
(very much improved) or 2 (much improved). Sustained response was defined 
as a response present at the end of the study that had lasted for 22 weeks. 
Patients were considered to be in remission if they achieved a HAM-D score 18. 
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Data from all patients who received 11 dose of study medication and who 
reported treatment-emergent AEs during the treatment period or within 7 days 
of the last dose were included in the analyses of study safety. Treatment- 
emergent AEs were defined as those not present, or present but less severe, at 
baseline. 
RESULTS 
A total of 149 consecutive patients (84 females, 65 males; mean age, 46.5 years; 
88 outpatients, 61 inpatients) were enrolled. The ITT population comprised 144 
patients (84 outpatients, 60 inpatients); 1 inpatient and 4 outpatients discon- 
tinued before postbaseline assessment and therefore were excluded because 
they failed to meet the requirements for eligibility for ITT. Before the first 
postbaseline assessment, 3 outpatients failed to return; 1 inpatient discontin- 
ued due to an AE; and 1 outpatient discontinued due to lack of efficacy. All 
patients (N = 149) were included in the tolerability analyses. Slightly more 
enrolled patients were women (55.7% of outpatients [49/88], 57.4% of inpatients 
[35/61]), and the distribution of mean age, body weight, and height was similar 
between both patient groups. The mean age was 46.5 years (range, 20-76 
years); mean body weight, 71.9 kg (range, 46-143 kg); and mean height, 168.8 
cm (range, 145.5-193.0 cm). 
Baseline Assessments 
A summary of the depression status of all patients (N = 149) at baseline is 
presented in Table I. At baseline, the mean (&SD) HAM-D score for outpatients 
was 22.7 k 3.5; for inpatients, 30.6 + 5.5. The mean (*SD) MADRS score for 
outpatients was 27.5 f 5.8; for inpatients, 35.3 * 6.8. According to the CC1 scale, 
most patients were moderately, markedly, or severely ill. A total of 40.9% of all 
patients (61/149; 54.5% of outpatients [48/88], 21.3% of inpatients [ 13/61]) were 
moderately ill; 37.6% of all patients (56/149; 36.4% of outpatients [32/88], 39.3% 
of inpatients [24/61]) were markedly ill; 16.1% of all patients (24/149; 6.8% of 
outpatients [6/88], 29.5% of inpatients [ 18/61]) were severely ill (Table I). 
Overall, 91.9% of all patients (137/149; 94.3% of outpatients [83/88], 88.5% of 
inpatients [54/61]) had received prior antidepressant therapy, the most com- 
mon type being selective serotonin reuptake inhibitors (SSRls; 78.5% of all 
patients [ 117/149]). 
Efficacy Assessments 
Of the 111 patients who completed the study (64 outpatients, 47 inpatients), the 
numbers of patients assessed using the HAM-D, MADBS, and CC1 scales were 
108 (63 outpatients, 45 inpatients), 107 (63 outpatients, 44 inpatients), and 108 
(63 outpatients, 45 inpatients), respectively. 
Significant improvements in mean total HAM-D scores were observed 
(P < O.OOl), with a mean reduction at week 8 of 15.4 f 8.1 for all patients. 
Significant mean decreases in the scores of the following items of the HAM-D 
scale were seen at week 8 for all patients: anxiety/somatization (3.0 f 2.5) 
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Table I. Baseline depression status in all study patients (N = 149). 
Parameter 
Inpatients Outpatients 
(n = 61) (n = 88) 
Duration of current episode 
of depression, no. (%) 
O-26 wk 41 (65.6) 59 (67.0) 
>26-52 wk 8 (13.1) 13 (14.8) 
>52 wk 6 (9.8) 15 (17.0) 
Unknown 6 (9.8) 1 (1.1) 
Mean HAM-D scale total score ? 
SD (range) 30.6 L 5.5 (22-47) 22.7 ? 3.5 (18-36) 
Mean MADRS total score ? SD 
(range) 35.3 rfr 6.8 (19-53) 27.5 -c 5.8 (12-45) 
CGI scale asssessment, no. (%) 
Mildly ill 0 (0.0) 2 (2.3) 
Moderately ill 13 (21.3) 48 (54.5) 
Markedly ill 24 (39.3) 32 (36.4) 
Severely ill 18 (29.5) 6 (6.8) 
Extremely ill 6 (9.8) 0 (0.0) 
Patients taking antidepressant 
medication before study, no. (%) 54 (88.5) 83 (94.3) 
HAM-D = Hamilton Depression; MADRS = Montgomery-Asberg Depression Rating Scale; CGI = Clinical 
Global Impression. 
depressed mood (2.0 + 1.2), sleep disturbance (1.7 f 2.2), suicidal ideation 
(1.2 f 0.9), retardation (0.8 f 0.9), and agitation (0.4 * 0.8) (I’< 0.001 for all). The 
percentage of patients with a HAM-D suicidal ideation score of 0 (ie, absent) 
increased significantly (P < 0.001) from 20.3% of ITT patients (29/143) at base- 
line to 80.6% (87/108) at week 8, and the rate of HAM-D-defined responders was 
71.3% (77/108; 71.4% of outpatients [45/63], 71.1% of inpatients [32/45]) at week 
8 and 56.3% (81/144; 54.8% of outpatients [46/84], 58.3% of inpatients [35/60]) at 
the final visit (LOCF). 
Significant improvements in mean total MADRS scores were observed from 
baseline to week 8 in both patient groups (Figure 1; P < O.OOl), with a mean 
decrease in MADRS score for all patients at week 8 of 19.7 * 10.9. The mean 
decrease in total MADRS scores in both groups at the final visit (LOCF) was 
16.1 f 12.4. The percentage of all patients with an MADRS suicidal ideation 
score of 0 (ie, absent) increased significantly (P < O.OOl), from 7.6% (1 l/144) at 
baseline to 69.2% (74/107) at week 8, and the rate of MADRS-defined responders 
was 73.8% (79/107; 71.4% of outpatients [45/63], 77.3% of inpatients [34/44]) at 
week 8 and 59.7% (86/144; 56.0% of outpatients [47/84], 65.0% of inpatients 
[39/60] at the final visit (LOCF). 
The rate of patients who were El-defined responders at week 8 was 78.7% 
(85/108) compared with 18.8% (26/138) at week 1. After 8 weeks of venlafaxine 











n Inpatients (n = 61) 
n Outpatients (n = 88) 
0 All patients (N = 149) *  c 
Baseline Week 1 Week 2 Week 3 Week 4 Week6 Week8 Final 
Visit 
Figure 1. Mean Montgomery-Asberg Depression Rating Scale (MADRS) scores for all pa- 
tients over the study period. *P < 0.001 versus baseline. 
administration, 69.4% of patients (75/108; 71.4% of outpatients [45/63], 66.7% of 
inpatients [30/45]) showed an overall response, with a sustained response 
observed in 33.3% of the ITT population (48/144; 33.3% of outpatients [28/84], 
33.3% of inpatients [20/60]). 
601 
n Inpatients (n = 61) 
n Outpatients (n = 88) 
0 All patients (N = 149) 
Week 1 Week 2 Week 4 Week 6 Week 8 Final 
Visit 
Figure 2. Rate of remissions as defined using the Hamilton Depression (HAM-D) scale 
(HAM-D score 58). (The results for week 3 were flawed; data not shown.) *P = 0.001 versus 
baseline; +P = 0.003 versus baseline; *P c 0.001 versus baseline. 
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By week 8, 45.4% of patients (491108; 50.8% of outpatients [32/63], 37.8% of 
inpatients [ 17/45]) were in remission as defined by a HAM-D score ~8 (Figure 
2). At the final on-therapy visit, the remission rate (LOW) was 35.4% for the ITT 
population (51/144; 39.3% of outpatients [33/84], 30.0% of inpatients [ 18/60]). 
Information on venlafaxine dosing is shown in Table II. The median maximum 
daily dose levels of venlafaxine attained were 150 mg/d in the outpatient group 
and 225 mg in the inpatient group. Among the outpatients, 65.9% (58/88) at- 
tained a maximum daily dose compared with 72.1% (44/61) of inpatients. 
Twelve (19.7%) inpatients had received a maximum daily dose of venlafaxine 
~225 mg. 
Safety Assessments 
Overall, 25.5% of all patients (38/149) withdrew from the study prematurely, 
with a slightly lower rate among inpatients (23.0% [14/61]) than outpatients 
(27.3% [24/88]). By week 1, 4.7% of patients (7/149) had withdrawn (5 due to 
AEs, 1 due to failure to return, and 1 due to an unsatisfactory response). 
By week 4, this rate had increased to 14.1% (21/149; 9 of these patients with- 
drew between weeks 3 and 4). By week 8, 16 additional patients had with- 
drawn (8 patients between weeks 4 and 6, and 8 patients between weeks 6 and 
8), with 24.8% of patients (37/149) withdrawn overall; 1 patient withdrew after 
week 8. The most common reasons for discontinuation were the occurrence of 
an AE (10.1% [ 15/149]) and unsatisfactory response (8.7% [ 13/149]). 
Venlafaxine was well tolerated at all doses, and the most frequently reported 
treatment-emergent AEs in all patients were nausea (24.2% [36/149]), sweating 
(12.1% [ 18/149]), and headache (10.1% [ 15/149]). Although inpatients received, 
on average, a higher maximum daily dose of venlafaxine than did outpatients, 
fewer inpatients reported treatment-emergent AEs (57.4% of inpatients [35/61], 
73.9% of outpatients [65/88]), with markedly lower occurrence rates of nausea, 
sweating, and headache. Most of these AEs were considered to be treatment 
related. 
No clinically significant changes in systolic or diastolic blood pressure val- 
ues were observed during the study. However, a substantial mean increase in 
Table II. Venlafaxine dosing information for all study patients (N = 149). 
Parameter inpatients (n = 61) Outpatients (n = 88) 
Mean dose + SD, mg/d 







156.5 -t 99.1 113.7 k 33.8 
5 (8.2) 28 (31.8) 
0 (0.0) 1 (1.1) 
17 (27.9) 26 (29.5) 
27 (44.3) 32 (36.4) 
12 (19.7) 1 (1.1) 
482 
M. Dierick et al. 
heart rate of 3.3 f 11.9 beats/min was observed for all patients at week 8. In 
total, 4.7% of patients (7/149) experienced increases or decreases of >7.0% in 
body weight in their baseline measurements at week 8. 
DISCUSSION 
The antidepressant efficacy of venlafaxine has been proved in both placebo- 
controlled and active comparator-controlled studiesS” The purpose of the 
present study was not only to confirm these findings but also to observe how 
the drug performed in clinical practice. Consecutive patients were enrolled in 
this Phase IV study to examine the use of venlafaxine within a representative 
population of depressed patients, as opposed to the highly selected patient 
populations examined in Phase 11 and III clinical trials. 
This study was run in psychiatric inpatient and outpatient settings; conse- 
quently, most patients had experienced prior depressive episodes and had 
been previously treated for depression. No comparator drug was used, and 
placebo was considered unethical for use in severely depressed patients. The 
use of open-label venlafaxine, combined with each investigator’s option to ad- 
just dose depending on the patient’s clinical response and tolerance, intro- 
duced the possibility of investigator bias and interinvestigator variability; how- 
ever, the results obtained support those previously observed in controlled 
clinical trials of venlafaxine. 
Most earlier studies have determined the efficacy of venlafaxine in terms of 
response, as defined by decreases in total HAM-D and MADRS scores 250% 
from baseline. However, the main focus of the present study was patient re- 
mission, defined as an end-of-study HAM-D score ~8. Indeed, of those patients 
who remained on venlafaxine therapy for 8 weeks, 50.8% (32/63) of outpatients 
and 37.8% (17/45) of inpatients achieved remission-a state that can be defined 
as virtually asymptomatic-despite moderate or severe depression scores at 
baseline. 
Although no comparator drug was used, this high level of remission confirms 
rates observed in previous studies of venlafaxine. In outpatients, Ballus et all5 
compared venlafaxine to paroxetine in patients with major depression or dys- 
thymia. At week 12 of treatment, significantly more patients in the venlafaxine- 
treated group than in the paroxetine-treated group had a HAM-D remission 
score ~8 (59% vs 31% of patients; P = 0.011). Results from a comparative study 
published by Mehtonen et al l6 also showed a statistically significantly higher 
(P < 0.05) remission rate (HAM-D score ~10) at week 8 for patients treated with 
venlafaxine (68% of patients) versus patients treated with sertraline (45% of 
patients). In a 6-week study in inpatients, Tzanakaki et all7 found higher remis- 
sion rates (HAM-D score ~7) with venlafaxine (41% of patients) compared with 
fluoxetine (36% of patients). Nierenberg et all8 assessed the use of venlafaxine 
in consecutive moderately depressed outpatients and inpatients who had failed 
to respond to previous antidepressant therapies. After 12 weeks of treatment, 
22% of patients remaining in the study were in remission. A meta-analysis of the 
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pooled results from 8 studies in which venlafaxine was compared with SSRIs 
showed more rapid and higher remission rates (HAM-D score ~7) with venla- 
faxine compared with the SSRIs analyzed.lg 
In the present study, significant improvements in mean total HAM-D and 
MADRS scores were seen for both patient groups (P < 0.001 for all), with a 
significantly greater percentage of patients having reduced HAM-D-defined sui- 
cidal ideation and retardation scores and MADRS total scores by week 8 com- 
pared with baseline (PC 0.001 for all). Because these 2 symptoms of depression 
often result in patient hospitalization, the significant improvements observed 
are of social and economic importance. In addition, improvements in mean 
individual HAM-D scores for anxiety/somatization, sleep disturbance, de- 
pressed mood, and agitation were noted in both outpatients and inpatients at 
week 8. 
Venlafaxine was well tolerated, particularly in inpatients, who received 
higher maximum daily doses than did outpatients but reported fewer AEs. The 
types of AEs experienced were as expected for patients receiving venlafaxine, 
with nausea, sweating, and headache reported most frequently. Overall, 25.5% 
(38/149) of patients withdrew from the study-10.1% due to AEs and 8.7% due 
to lack of efficacy. Compared with other studies in patients with similar levels 
of depression,” this rate of withdrawal was low. No anticipated significant 
abnormalities in blood pressure occurred during the course of the study, fur- 
ther demonstrating the tolerability of venlafaxine. 
CONCLUSION 
The results of this study suggest that venlafaxine was a tolerable and effective 
antidepressant, which was able to provide remission and symptom relief in a 
significant proportion of moderately or severely depressed inpatients and out- 
patients in a natural setting. 
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